JENKEM(SH:688356)2022-03-30 16:00Dividend and Profit Distribution - The company plans to distribute a cash dividend of 8.79 RMB per 10 shares, totaling approximately 52,740,000 RMB, which represents 30% of the net profit attributable to shareholders for 2021[7]. - The total share capital for the dividend calculation is estimated at 60,000,000 shares, subject to adjustment based on the actual share capital on the dividend record date[7]. - The company has not proposed any capital reserve transfer to increase share capital or stock dividends for 2021[7]. - The company has a cash dividend policy that prioritizes cash dividends at a minimum of 80% for mature stages without major capital expenditures, 40% with major expenditures, and 20% for growth stages with major expenditures[198]. - The company must have positive distributable profits and no significant investment plans to qualify for cash dividends, with a minimum annual cash distribution of 10% of the current year's distributable profits[198]. Financial Performance - The company's total revenue for 2021 was approximately ¥351.19 million, representing an 88.18% increase compared to ¥186.62 million in the previous year[32]. - Net profit attributable to shareholders for 2021 was approximately ¥175.78 million, a 105.16% increase from ¥85.68 million in 2020[32]. - The net cash flow from operating activities for 2021 was approximately ¥118.23 million, reflecting a 51.16% increase from ¥78.22 million in the previous year[32]. - The company's total assets at the end of 2021 were approximately ¥1.10 billion, a 22.27% increase from ¥900.61 million at the end of 2020[32]. - The basic earnings per share for 2021 was ¥2.93, a 71.35% increase compared to ¥1.71 in 2020[34]. - The weighted average return on equity for 2021 was 18.47%, a slight decrease of 0.73 percentage points from 19.20% in 2020[34]. - The net profit attributable to shareholders increased by 105.16% year-on-year, while the net profit after deducting non-recurring gains and losses grew by 89.74%[37]. - Basic earnings per share increased by 57.83% year-on-year, with diluted earnings per share rising by 69.49%[37]. - The gross profit margin for the main business was 85.21% during the reporting period[78]. - The company's gross profit margin for 2021 was 85.21%, a decrease of 0.76 percentage points from the previous year[87]. Research and Development - The R&D expenditure as a percentage of total revenue for 2021 was 15.37%, an increase of 1.28 percentage points from 14.09% in 2020[34]. - The company invested a total of 53.97 million yuan in R&D, representing a 105.22% increase year-on-year, with R&D expenses accounting for 15.37% of sales revenue[47]. - The company submitted 17 new patent applications and obtained 12 new authorizations during the year[47]. - The company achieved a total R&D investment of ¥53,968,557.23, representing a 105.22% increase compared to the previous year[65]. - The number of R&D personnel increased to 58, representing 27.9% of the total workforce, up from 18.3% in the previous year[70]. - The company completed the development of 50 new structural derivatives and optimized 21 derivative products during the reporting period[126]. - The company is focusing on the development of innovative polyethylene glycol-modified drugs and medical devices, with ongoing R&D investments[78]. Market and Sales Performance - The company experienced rapid growth in domestic product sales due to increased orders from major clients, contributing to the overall revenue increase[34]. - International product sales also grew rapidly, driven by stable order increases from overseas clients and new product orders from newly developed customers[34]. - Domestic revenue was 165 million yuan, a 79.44% increase, primarily from increased sales of products and technical service fees[100]. - International revenue reached 186 million yuan, up 96.73%, due to stable order growth from overseas clients and new product orders[100]. - The top five customers accounted for 63.66% of total sales, with the largest customer contributing ¥5,655.49 million, or 16.10%[105]. Corporate Governance - The company has established a comprehensive corporate governance system, including rules for the shareholders' meeting, board of directors, and supervisory board, ensuring clear responsibilities and procedures[156]. - The company held a total of 4 shareholder meetings in 2021, including 1 annual meeting and 3 extraordinary meetings, ensuring compliance with legal regulations and protecting minority shareholders' rights[159]. - The board of directors convened 9 meetings in 2021, adhering to legal and regulatory requirements, which enhanced the board's operational standards and decision-making processes[159]. - The company disclosed significant information accurately and timely, maintaining transparency and protecting the interests of minority investors[156]. - The company implemented a strict insider information management system to limit the number of individuals with access to sensitive information[156]. Risks and Challenges - The company faces risks related to market competition and potential declines in gross profit margin due to rising production costs[78]. - The company faced a risk of increased tax rates if it fails to maintain its high-tech enterprise status, which currently allows for a 15% corporate income tax rate[81]. - The company's products are significantly impacted by U.S. trade policies, with 60.34% of sales revenue derived from the U.S. market[83]. Future Outlook and Strategy - The company plans to continue expanding its market presence and enhancing its product offerings through ongoing R&D efforts[34]. - The company aims to enhance its technical innovation capabilities and maintain a leading position in the PEG-derived drug industry by focusing on continuous innovation and exploring new application scenarios[145]. - Over the next three years, the company plans to strengthen its R&D capabilities by increasing investments in advanced equipment, research funding, and human resources to improve market responsiveness[149]. - The company will focus on the production and sales of PEG-derived drugs while providing technical services and preclinical solutions, aiming to accelerate the development of proprietary products[149]. - The company intends to enhance its market presence by increasing marketing investments and optimizing service processes to improve service quality[149].